According to the subgroup Examination, we identified that there was sizeable heterogeneity regarding mortality, favorable results, and the whole treatment method productive rate. Relating to mortality, The key reason why for heterogeneity on the subgroup of edaravone dexborneol and EDV was largely attributed to distinctions in drug dosage. Relating to https://louismeyqp.popup-blog.com/32441908/not-known-facts-about-neuroprotectives-for-sale-online-europe